FDA offers an olive branch on 'modernization'

WASHINGTON - Having nearly wrapped-up negotiations with industry for a new version of the Prescription Drug User Fee Act (PDUFA), FDA has reached out to the biotechnology and pharmaceutical industries with an offer to jointly craft new FDA reform legislation.

At a meeting at FDA headquarters with top agency officials on Friday, Biotechnology Industry Organization President Carl Feldbaum and Pharmaceutical Research and Manufacturers of America President Alan Holmer were invited to join the agency in

Read the full 746 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE